trial · primary record
TVB-2640
Prostatic Neoplasms, Castration-Resistant
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 8 |
| Primary completion | 2028-01-25 |
| Primary endpoint | Optimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD) |
| Registry ID | NCT05743621 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:28:30.854Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05743621
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.